Turn Therapeutics Consensus Price Target Increased by 24.42% to $20.40
Published . Updated .
The average one-year price target for Turn Therapeutics (NASDAQGM:TTRX) has been revised to $20.40 / share. This is an increase of 24.42% from the prior estimate of $16.40 dated September 11, 2026. These figures represent aggregate analyst targets and do not constitute a recomme
Directly affected
- TTRX Turn Therapeutics
Named in this report.
Indirectly affected
- ITDE ISHARES LIFEPATH TARGET DATE 2045 ETF USD
GA selected ITDE as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- FGSI FT VEST GROWTH STRENGTH & TARGET INCOME ETF
GA selected FGSI as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ITDB ISHARES LIFEPATH TARGET DATE 2030 ETF
GA selected ITDB as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ITDC ISHARES LIFEPATH TARGET DATE 2035 ETF USD
GA selected ITDC as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BTCZ T-Rex 2X Inverse Bitcoin Daily Target ETF
GA selected BTCZ as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DOGG FT VEST DJIA DOGS 10 TARGET INCOME ETF
GA selected DOGG as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
The average one-year price target for Turn Therapeutics (NASDAQGM:TTRX) has been revised to $20.40 / share. This is an increase of 24.42% from the prior estimate of $16.40 dated September 11, 2026. These figures represent aggregate analyst…
Source: Nasdaq Markets
The price since 3 Oct 2026: Turn Therapeutics (TTRX) versus the S&P 500
Since the first closing price after “Turn Therapeutics Consensus Price Target Increased by 24.42% to $20.40,” Turn Therapeutics (TTRX) is -13.72%. The S&P 500 fund (SPY) is -1.08% over the same days, a -12.64% difference versus the market.
Who gains and who loses around Turn Therapeutics (TTRX)
Companies carried with this story
- TTRX Turn Therapeutics
For “Turn Therapeutics Consensus Price Target Increased by 24.42% to $20.40,” Turn Therapeutics (TTRX) is linked, with no stored direction, high confidence. Reason on file: The reported development directly names TURN THERAPEUTICS INC in the headline; GA resolved that company to TTRX
- ITDE Ishares Lifepath Target Date 2045 Etf Usd
For “Turn Therapeutics Consensus Price Target Increased by 24.42% to $20.40,” Ishares Lifepath Target Date 2045 Etf Usd (ITDE) is linked, with no stored direction, medium confidence. Reason on file: GA selected ITDE as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- FGSI Ft Vest Growth Strength & Target Income Etf
Ft Vest Growth Strength & Target Income Etf (FGSI) is linked, with no stored direction, medium confidence in the 3 Oct 2026 story “Turn Therapeutics Consensus Price Target Increased by 24.42% to $20.40.” Reason on file: GA selected FGSI as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ITDB Ishares Lifepath Target Date 2030 Etf
In “Turn Therapeutics Consensus Price Target Increased by 24.42% to $20.40,” Ishares Lifepath Target Date 2030 Etf (ITDB) is linked, with no stored direction, medium confidence. Reason on file: GA selected ITDB as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ITDC Ishares Lifepath Target Date 2035 Etf Usd
In “Turn Therapeutics Consensus Price Target Increased by 24.42% to $20.40,” Ishares Lifepath Target Date 2035 Etf Usd (ITDC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ITDC as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BTCZ T-Rex 2X Inverse Bitcoin Daily Target ETF
For “Turn Therapeutics Consensus Price Target Increased by 24.42% to $20.40,” T-Rex 2X Inverse Bitcoin Daily Target ETF (BTCZ) is linked, with no stored direction, medium confidence. Reason on file: GA selected BTCZ as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DOGG Ft Vest Djia Dogs 10 Target Income Etf
For “Turn Therapeutics Consensus Price Target Increased by 24.42% to $20.40,” Ft Vest Djia Dogs 10 Target Income Etf (DOGG) is linked, with no stored direction, medium confidence. Reason on file: GA selected DOGG as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Turn Therapeutics (TTRX)
“Turn Therapeutics Consensus Price Target Increased by 24.42% to $20.40” (3 Oct 2026) reaches Turn Therapeutics (TTRX) through this story.
Turn Therapeutics (TTRX) is on the page because The reported development directly names TURN THERAPEUTICS INC in the headline; GA resolved that company to TTRX
Ishares Lifepath Target Date 2045 Etf Usd (ITDE) is here too. Its reason reads: GA selected ITDE as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Price levels for Turn Therapeutics (TTRX)
FGSI traded between 20.20 and 20.62 across 5 sessions. The latest close on file is 20.27. ITDE traded between 39.73 and 40.87 across 19 sessions. The latest close on file is 39.95. TTRX traded between 10.26 and 15.40 across 20 sessions. The latest close on file is 10.72.
A simple score for Turn Therapeutics (TTRX)
46 out of 100
“Turn Therapeutics Consensus Price Target Increased by 24.42% to $20.40” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.